Home › Steatotic Liver Disease › Florida
Steatotic Liver Disease clinical trials in Florida
20 studies for Steatotic Liver Disease are looking for participants at sites in Florida.
Cities in Florida
- Miami16 studies
- Hialeah9 studies
- Orlando9 studies
- Ocala8 studies
- Cape Coral6 studies
- Sarasota6 studies
- West Palm Beach5 studies
- Jacksonville5 studies
- Spring Hill4 studies
- Brandon4 studies
- Doral4 studies
- Homestead4 studies
- Gainesville3 studies
- Deltona3 studies
- Melbourne3 studies
- St. Petersburg3 studies
- The Villages3 studies
- Kendall3 studies
- Lakeland3 studies
- Town 'n' Country3 studies
- Boca Raton3 studies
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami
- GSK Investigational Site, Ocala
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami
- GSK Investigational Site, Ocala
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- Health Awareness, Inc, Jupiter
- Evolution Clinical Trials, Miami
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07527910Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- University of Miami Health System, Miami
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Evolution Clinical Trials, Hialeah Gardens
- Health Awareness, inc., Jupiter
- Genoma Research Group, Inc., Miami
- and 2 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- K2 Medical Research WINTER GARDEN, Clermont
- K2 Medical Research - Daytona Beach, Daytona Beach
- Care Access - Delray Beach, Delray Beach
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Bradenton
- Akero Clinical Study Site, Brandon
- Akero Clinical Study Site, Cutler Bay
- and 23 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Boynton Beach
- GSK Investigational Site, Cape Coral
- GSK Investigational Site, Clermont
- and 19 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Synergy Healthcare, Bradenton
- Synergy Healthcare, Bradenton
- Health Awareness, Inc., Jupiter
- and 6 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Clermont
- 89bio Clinical Study Site, Fort Myers
- 89bio Clinical Study Site, Gainesville
- and 15 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Brandon
- 89bio Clinical Study Site, Clermont
- 89bio Clinical Study Site, Fort Myers
- and 15 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
- AdventHealth Translational Research Institute, Orlando
RecruitingHealthy volunteers welcome
Ages 25 to 55 · All sexes · Updated Aug 12, 2026 · NCT06993454A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Brandon
- GSK Investigational Site, Miami
- GSK Investigational Site, Miami Lakes
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Boynton Beach
- GSK Investigational Site, Cape Coral
- GSK Investigational Site, Clermont
- and 20 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Miami
- GSK Investigational Site, Viera
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, Tampa
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Jun 9, 2026 · NCT07358546A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Genoma Research Group, Inc, Miami
- Med Research of Florida, LLC, Miami
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Apr 16, 2026 · NCT05648214Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- Clinical Pharmacology of Miami, Miami
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Aug 14, 2025 · NCT07122700Low-Dose Pioglitazone in Patients With NASH (AIM 2)
- University of Florida, Gainesville
RecruitingPhase 2
Ages 21 to 75 · All sexes · Updated Apr 4, 2025 · NCT04501406AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- AdventHealth Translational Research Institute, Orlando
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Mar 13, 2025 · NCT04807868From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.